Clinical trial
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
NCT00454363 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00454363 |
|---|---|
| Title | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer |
| Official title | A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1 and 1 more |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study |
| Enrollment | 52 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Mar 30, 2007 |
| Last update posted | Apr 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: